Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, In Vivo
UK
+7 year(s) experience
In Vivo
By Lucie Ellis 01 Feb 2019
With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.
Topic BioPharmaceutical Drug approval Drug development landscape Drug review
In Vivo
By Lucie Ellis 22 Aug 2018
Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.
In Vivo
By Lucie Ellis 17 Aug 2018
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
Topic Drug approval Drug review
Scrip
By Lucie Ellis 24 Apr 2018
Scrip investigates the big issues Israel's biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.
Topic BioPharmaceutical
Scrip
By Lucie Ellis 23 Feb 2018
As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.
Topic Business strategies
Scrip
By Lucie Ellis 21 Feb 2018
In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.
Topic Cancer
Scrip
By Lucie Ellis 13 Feb 2018
Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.
Scrip
By Lucie Ellis 22 Dec 2017
Ray Barlow talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin.
Scrip
By Lucie Ellis 18 Oct 2017
Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product
Scrip
By Lucie Ellis 04 Oct 2017
With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy
Topic Rare Disease
Scrip
By Lucie Ellis 23 Sep 2017
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer
Topic Cancer
Scrip
By Lucie Ellis 27 Jul 2017
In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.
Topic Business strategies
Scrip
By Lucie Ellis 27 Jul 2017
Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.
Scrip
By Lucie Ellis 26 Jun 2017
AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe.
Scrip
By Lucie Ellis 23 Mar 2017
Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.
In Vivo
02 Jan 2019
In Vivo
19 Dec 2018
Scrip
11 Dec 2018
In Vivo
17 Oct 2018
In Vivo
08 Oct 2018
Scrip
18 Sep 2018
In Vivo
13 Aug 2018
Scrip
30 May 2018
Scrip
25 May 2018
Scrip
23 May 2018
Scrip
21 May 2018
Scrip
18 May 2018
Scrip
17 May 2018
Scrip
16 May 2018
Scrip
14 May 2018
